Results From REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 03期
关键词：
ACUTE GVHD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：3
相关论文
共 50 条
  • [11] Ruxolitinib for Steroid-Refractory Acute Graft-Versus-Host Disease: A Single Centre Retrospective Study
    Suo, Yuan
    Liu, Jiapei
    Sun, Yiming
    Wu, Qiaoyuan
    Jin, Hua
    Liu, Qifa
    BLOOD, 2021, 138
  • [12] Safety analysis of Ruxolitinib (RUX) vs Best Available Therapy (BAT) in patients (pts) with Steroid-Refractory (SR) acute Graft-vs-Host Disease (aGVHD) in the randomized phase 3 REACH2 study
    von Bubnoff, N.
    Butler, J.
    Wagner, E.
    Forcade, E.
    Sanz, J.
    Russo, D.
    Grillo, G.
    Zuckerman, T.
    Bozdag, Civriz S.
    Ayuk, F.
    Stoelzel, F.
    Yoon, S-S
    Garcia-Gutierrez, V
    Ritchie, D.
    Bulabois, C-E
    Rubio, M-T
    Xu, J.
    Morando, J.
    Mahuzier, B.
    Chandraiah, Mahadevaiah S.
    Socie, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 230 - 231
  • [13] Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study
    Von Bubnoff, Nikolas
    Butler, Jason P.
    Wagner, Eva Maria
    Forcade, Edouard
    Caballer, Jaime Sanz
    Russo, Domenico
    Grillo, Giovanni
    Zuckerman, Tsila
    Bozdag, Sinem Civriz
    Ayuk, Francis A.
    Stoelzel, Friedrich
    Yoon, Sung-Soo
    Gutierrez, Jose Valentin Garcia
    Ritchie, David
    Bulabois, Claude-Eric
    Rubio, Marie Therese
    Xu, Judith
    Morando, Juliane
    Mahuzier, Bruyere
    Chandraiah, Satish Mahadevaiah
    Socie, Gerard
    BLOOD, 2020, 136
  • [14] Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
    Socie, Gerard
    Niederwieser, Dietger
    Von Bubnoff, Nikolas
    Mohty, Mohamad
    Szer, Jeffrey
    Or, Reuven
    Butler, Jason P.
    Wagner, Eva Maria
    Forcade, Edouard
    Caballer, Jaime Sanz
    Russo, Domenico
    Grillo, Giovanni
    Zuckerman, Tsila
    Bozdag, Sinem Civriz
    Ritchie, David
    Chaturvedi, Shalini
    Prahallad, Anirudh
    Sinclair, Karen
    Wilke, Celine
    Zeiser, Robert
    BLOOD, 2020, 136
  • [15] Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience
    Wang, Yi-Lun
    Chang, Tsung-Yen
    Wen, Yu-Chuan
    Yang, Shu-Ho
    Hsiao, Yi-Wen
    Chen, Shih-Hsiang
    Jaing, Tang -Her
    PEDIATRICS AND NEONATOLOGY, 2024, 65 (01): : 85 - 86
  • [16] Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
    Wu, Hengwei
    Shi, Jimin
    Luo, Yi
    Tan, Yamin
    Zhang, Mingming
    Lai, Xiaoyu
    Yu, Jian
    Liu, Lizhen
    Fu, Huarui
    Huang, He
    Zhao, Yanmin
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [17] Biomarker analysis in patients with steroid-refractory/dependent chronic graft-vs-host disease treated with ruxolitinib or best available therapy in the randomized phase 3 REACH3 study
    Locatelli, F.
    Zeiser, R.
    Teshima, T.
    Prahallad, A.
    Sinclair, K.
    Stefanelli, T.
    Lee, S. J.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 41 - 42
  • [18] Alemtuzumab as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease: Results of a Phase II Study
    Martinez, Carmen
    Solano, Carlos
    Ferra, Christelle
    Sampol, Antonio
    Valcarcel, David
    Antonio Perez-Simon, Jose
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (05) : 639 - 642
  • [19] Ruxolitinib for pediatric patients with treatment-naive and steroid-refractory acute graft-versus-host disease: the REACH4 study
    Locatelli, Franco
    Kang, Hyoung Jin
    Bruno, Benedicte
    Gandemer, Virginie
    Rialland, Fanny
    Faraci, Maura
    Takahashi, Yoshiyuki
    Koh, Katsuyoshi
    Bittencourt, Henrique
    Cleary, Grace
    Rosko, Christine
    Li, Xuechan
    St Pierre, Annie
    Prahallad, Anirudh
    Diaz-de-Heredia, Cristina
    BLOOD, 2024, 144 (20) : 2095 - 2106
  • [20] Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study
    Martinez, C.
    Solano, C.
    Ferra, C.
    Sampol, A.
    Valcarcel, D.
    Perez-Simon, J. A.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S132 - S132
12345